Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: interferon beta-1b, interferon alfa-2b, interferon alfa-n3 +9 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 10 Parkinson's papers of 1,370 | 0.69 |
| pathways Reactome | 5 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6935
Sealed predictions
- IFNAR1 in dopamine neurons, braak-0.12 (p 0.749) → -0.52 (p 0.149)receipt 6942
Swarm cases
receipt 6942: IFNAR1 in dopamine neurons, braak
- power
- full sample -0.28 (p 0.258, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.250, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.26 (p 0.298, n 18). could be the mix.
- skeptic
- leave-one-out range -0.44 to -0.20, sign flips 0; without severely affected donors -0.28 (p 0.258, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.61 (p 0.0069, n 18) vs -0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IFNAR1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up IFNAR1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.18 p 0.534 (needs p < 3.0e-4)
Receipts
loading the receipts